Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults

Istúriz, Raúl; Webber, Chris

doi:10.1080/21645515.2015.1043502

Cited by 18 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A randomized placebo-controlled trial (CAPiTA trial) conducted in the Netherlands verified the clinical benefit of PCV13 in the prevention of vaccine-type community-acquired pneumonia (46%), nonbacteremic/noninvasive pneumococcal pneumonia (45%), and invasive pneumococcal disease (75%) among adults aged ≥ 65 years 11 . The report of CAPiTA trial was presented to the US Advisory Committee on Immunization Practices (ACIP) in June 2014, which subsequently recommended sequential PCV13 and 23-valent pneumococcal polysaccharide vaccination for adults ≥ 65 years in August, 2014 10,12 . Several RCTs conducted in the US and Europe among older adults showed that PCV13 induced an immune response as good as or better than that induced by PPSV23, and that both have similar safety profiles 33,34 …”

Section: Discussionmentioning

confidence: 99%

“…The second vaccine, the 13-valent pneumococcal conjugate vaccine (PCV13), which has been used among children since 2010, was approved by FDA in December 2011 for use in those aged ≥ 50 years 9 . A randomized placebo-controlled trial (CAPiTA trial) was conducted in the Netherlands, and verified the clinical benefit of PCV13 in the prevention of vaccine-type community-acquired pneumonia (46%), nonbacteremic/noninvasive pneumococcal pneumonia (45%), and invasive pneumococcal disease (75%) among adults aged ≥ 65 years 10,11 . The report of CAPiTA trial was presented to the US Advisory Committee on Immunization Practices (ACIP) in June 2014, which subsequently recommended sequential PCV13 and PPV23 vaccination in August, 2014 for adults ≥ 65 years of age 12 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: A meta-analysis

Zhang

Tang

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The purpose of this study was to perform a meta-analysis comparing the effectiveness of influenza vaccination alone versus influenza plus pneumococcal dual vaccination for the prevention of pneumonia and mortality in adults ≥ 65 years of age. Medline, Cochrane, CENTRAL, EMBASE, and Google Scholar databases were searched. Inclusion criteria were: 1) Randomized controlled trials (RCTs), 2-arm prospective studies, or retrospective cohort studies; 2) Patients were ≥ 65 years of age with or without chronic respiratory disease; 3) Patients received the influenza vaccine alone or dual pneumococcal and influenza vaccination; 4) Results included incidence of recurrent respiratory tract infections, length of hospital stay, and overall mortality rate. The outcomes were pneumonia and all-cause mortality rates. Of 142 studies identified in the database searches, 6 were ultimately included in the systematic review, and 5 were included in meta-analysis. The number of patients that received the influenza vaccination alone ranged from 211 to 29,346 (total = 53,107), and the number that received influenza+pneumococcal vaccination ranged from 246 to 72,107 (total = 102,068). Influenza+pneumococcal vaccination was associated with a significantly lower pneumonia rate than influenza vaccination alone (relative risk [RR] = 0.835, 95% confidence interval [CI]: 0.718–0.971, P = 0.019), and with a significantly lower all-cause mortality rate than influenza vaccination alone (relative risk [RR] = 0.771, 95% confidence interval [CI]: 0.707–0.842, P = 0.001). In conclusion, the results of this study support concomitant pneumococcal and influenza vaccination of the elderly as a dual vaccination strategy is associated with lower pneumonia and all-cause mortality rates.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: A meta-analysis

Zhang

Tang

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Several studies have shown the effectiveness of influenza vaccination in reducing antimicrobial use and antimicrobial resistance [17, 18]. Similar evidence exists for pneumococcal conjugate vaccine (PCV) use in older adults, which can reduce episodes of pneumonia [19]. Further study on vaccination to reduce AMR in this city is needed.…”

Section: Discussionmentioning

confidence: 98%

The impact of the national action plan on the epidemiology of antibiotic resistance among 352,238 isolates in a teaching hospital in China from 2015 to 2018

Wang

Little

et al. 2019

Antimicrob Resist Infect Control

View full text Add to dashboard Cite

BackgroundWe sought to understand the epidemiology and characteristics of antimicrobial resistance (AMR) and the impact of the National Action Plan (NAP) on AMR. This information will be critical to develop interventions and strengthen antibiotic stewardship in hospital settings in China.MethodsCross-sectional data collection from the hospital information management system from 1 January 2015 to 30 August 2018. Variables included patient age, sex, diagnosis, hospital department and antibiotic sensitivity test. T-test for two samples method was applied to compare the results before and after NAP implementation. Multivariate analysis with binary logistic regression was conducted to examine the associations of risk factors for antimicrobial resistance.ResultsIn total there were 352,238 isolates in the final analysis after excluding contamination strains and isolates with incomplete information. More than 50% of patients were > 66 years old. 62% were male. 40% of the total samples were sputum. Among the total sample, the total resistance rate was 42% among all isolates. The rate of resistance to all antibiotics declined by 5.3% (95% CI 4.96–5.64%, p < 0.0001) and culture positivity rate declined by 9.8% (95% CI 9.22–10.34%, p < 0.0001) after NAP. Logistical regression showed that the NAP had effect with an adjusted odds ratio of 0.76 (95% CI 0.71–0.81, p = 0.002). Being male, age > 65 years, ICU department, diagnosed with certain diseases were more likely to be associated with antimicrobial resistance.ConclusionsAntibiotic resistance rates were high in this teaching hospital. However, the introduction of the China NAP since 2016 followed by hospital policy emphasis was associated with a declining AMR trend. Policies will need to incorporate antimicrobial stewardship with a focus on certain departments, with infection control practices and with increases in vaccination coverage among elderly.

show abstract

“…30 Not surprisingly, several (41%, 14/34) of the predictors of mortality identified are consistent with conditions that also increase the risk for development of invasive pneumococcal disease, and thus support current ACIP recommendations for the vaccination of adults against pneumococcal disease. [31][32][33] Although pneumococcal vaccination is primarily intended to prevent development of disease, a recent study demonstrated that implementation of programs to increase vaccination with both the 23-valent polysaccharide pneumococcal vaccine and the 13-valent pneumococcal conjugate vaccine have resulted in not only decreased incidence of invasive pneumococcal disease but also mortality. 26 Vaccination strategies utilizing both vaccines may minimize negative outcomes, including mortality.…”

Section: Discussionmentioning

confidence: 99%

“…2 As neurologic disorders were also independent predictors of mortality in this study, and considering the infection and potential mortality prevention afforded by pneumococcal vaccination, further studies assessing the impact of pneumococcal vaccination on outcomes in patients with a history of neurologic disorders are warranted. [25][26][27]33 Fluid and electrolyte disorders, chronic pressure ulcers, and MRSA or Gram-negative infections were also predictive of mortality. Fluid and electrolyte disorders, which may also be related to renal dysfunction, were predictive both during hospitalization as well as within 1 year of culture.…”

Section: Discussionmentioning

confidence: 99%

Predictors of Mortality Among U.S. Veterans With Streptococcus Pneumoniae Infections

Morton

Morrill

LaPlante

et al. 2017

American Journal of Preventive Medicine

View full text Add to dashboard Cite

Introduction: Serious Streptococcus pneumoniae infections, encompassing pneumonia, bacteremia, and meningitis, are a major cause of mortality. However, literature regarding mortality is often limited to invasive pneumococcal disease, excluding pneumonia. This study sought to identify predictors of mortality among adults with serious pneumococcal disease, including pneumonia and invasive pneumococcal disease. Methods

show abstract

Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults

Cited by 18 publications

References 16 publications

Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: A meta-analysis

Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: A meta-analysis

The impact of the national action plan on the epidemiology of antibiotic resistance among 352,238 isolates in a teaching hospital in China from 2015 to 2018

Predictors of Mortality Among U.S. Veterans With Streptococcus Pneumoniae Infections

Contact Info

Product

Resources

About